Victrelis Boceprevir What Is
Victrelis™ (boceprevir) and Hepatitis C
What is Victrelis™ (boceprevir)?
On May 13, 2011, the U.S. Food and Drug Administration approved the prescription medication Victrelis™ (boceprevir) for use in combination with peginterferon alfa and ribavirin to treat chronic Hepatitis C genotype 1 infection in those who have not been treated before or who have failed previous Hepatitis C treatment. The active ingredient in this 200 mg capsule is boceprevir.
Victrelis™ is a Hepatitis C virus (HCV) NS3/4A protease inhibitor to be used in combination with peginterferon alfa and ribavirin. Victrelis™ is a direct acting antiviral drug against the Hepatitis C virus. It is indicated for adult patients with Hepatitis C, who have not been treated or who have failed previous interferon and ribavirin therapy.